BioAge Labs Inc

BioAmber, Inc. is an industrial biotechnology company, which produces sustainable chemicals. Its proprietary technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstock into chemicals for use in everyday products, including plastics, resins, paints, food additives and personal care products. The firm's products include bio-based succinic acid, butanediol and bio-based disodium succinate. The company was founded on October 15, 2008 and is headquartered in Montreal, Canada.

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Richmond, CA.

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity Completed $238.3 million initial public offering and concurrent private placement, cash and cash equivalents sufficient to fund operations and capital expenditures into 2029 Appointed former GSK CEO Jean-Pierre Garnier as Board Chair RICHMOND, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today provided business updates and reported its third quarter 2024 financial results.

BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates

Recursion Pharmaceuticals

Prediction: These 2 Stocks Could Soar in 2025

The future of the weight loss market might not revolve around GLP-1 drugs.

GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom

BioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm.

Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock

Eli Lilly

One of these businesses is a risky play, but the other is very likely to succeed.

2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Now

Southwest Airlines

New Fortress Energy

Talos Energy Inc

TKO Group Holdings Inc

Wave Life Sciences

24/7 Wall St. Insights Public offerings of stock and activist investor activity have prompted some huge insider buying.

An Airline, Biotechs, and More See Huge Insider Buying

There's a chance that its lead candidate could become one of the top drugs ever.

3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October

BioAge has its eyes on a handful of truly gargantuan markets.

This IPO Biotech Stock Could Be the Next Eli Lilly

RICHMOND, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of aging, today announced the closing of its upsized initial public offering of 12,650,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 1,650,000 additional shares, at the initial public offering price of $18.00 per share. All of the shares were offered by BioAge.

BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of the Concurrent Private Placement

The biotech sector is reviving, with IPOs reappearing and BioAge Labs' weight loss drug, Azelaprag, showing market potential. Biotech stocks are volatile, facing challenges like regulatory hurdles and high borrowing costs, exacerbated by interest rate hikes. The Federal Reserve's rate cuts have improved borrowing conditions, leading to a surge in biotech IPOs and a 53% rise in biotech stocks since October 2023.

BioAge Labs: Weighing The Risks And Rewards Of A Biotech Revival

BKV Corp

BingEx Ltd

FrontView REIT Inc

Guardian Pharmacy Services Inc

Premium Catering Holdings Ltd

SAG Holdings Ltd

Standardaero Inc

Three IPOs each raised at least $100 million this week, in a welcome bump in activity. Four IPOs and two SPACs submitted initial filings this past week. Six IPOs are currently scheduled to list in the week ahead.

U.S. IPO Weekly Recap: 3 Sizable Deals Trade Up

BioAge Labs stock rallied Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity treatments.

BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rallies 28% On Upsized IPO

Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.

BioAge valued at $758 mln in debut as investors bet on weight-loss drug frenzy

BioAge Labs is having its initial public offering today. The drug developer's signature product, Azelaprag, isn't yet on sale, but it is undergoing clinical trials in hopes it will one day be.

BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq

Texas-based Barnett Shale driller prices below the estimated range, while obesity-drug developer BioAge prices midrange ahead of trading.

Natural-gas producer BKV and drug-developer BioAge queue up IPOs

BioAge Labs has raised $198 million after pricing its upsized U.S. initial public offering at the midpoint of the range at $18 per share, the weight-loss drug developer said on Wednesday.

Weight-loss drug developer BioAge raises $198 mln in U.S. IPO

RICHMOND, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of aging, today announced the pricing of its upsized initial public offering of 11,000,000 shares of its common stock at a public offering price of $18.00 per share. All of the shares are being offered by BioAge. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $198.0 million.

BioAge Labs Announces Pricing of Upsized Initial Public Offering

BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong demand from investors.

Obesity drug developer BioAge Labs targets up to $640 mln valuation in upsized US IPO

Global Engine Group Holding Ltd

Kairos Pharma Ltd

Legacy Education Inc

VanEck

Two small IPOs and two SPACs debuted this past week - Global Engine, Kairos Pharma, YHN Acquisition I, and Cayson Acquisition, respectively. Seven IPOs and three SPACs submitted initial filings. Eight companies are expected to price their IPOs in the upcoming week, including three larger deals.

U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost

Bicara Therapeutics Inc

Powell Max Ltd

Pheton Holdings Ltd

Zenas Biopharma Inc

Two small IPOs and two SPACs debuted this past week - Pheton Holdings, Powell Max, Vine Hill Capital, and Andretti Acquisition II, respectively. Eight IPOs submitted initial filings this past week, including three names that filed to raise $100 million or more. Two biotechs are scheduled to complete IPOs next Thursday, each aiming to raise $200 million.

U.S. IPO Weekly Recap: 2 APAC Microcaps Go Public In Short Labor Day Week As The Pipeline Grows

BioAge Labs, Inc. is seeking $100 million in an IPO to fund its clinical trials for obesity and insulin sensitivity treatments. The company's lead drug, Azelaprag, is in Phase 2 trials, with promising early results and strong backing from well-known investors. The global obesity treatment market is projected to grow significantly, driven by an aging population and increased health awareness.

BioAge Labs Readies $100 Million IPO Plan For Obesity Treatment

News for BioAge Labs Inc Stock (BIOA)